Securities code: Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) securities abbreviation: Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Announcement No.: 2022020 Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd
Special report on the deposit and actual use of the company’s raised funds in 2021
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
In accordance with the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies, the guidelines for the self-discipline supervision of listed companies on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation, and the Listing Rules of shares on the science and innovation board of Shanghai Stock Exchange, The board of directors of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as “the company” or “the company”) explained the special report on the deposit and actual use of raised funds in 2021 as follows:
1、 Basic information of raised funds
(I) amount of actually raised funds and arrival time
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as “the company” or “the company”) was examined and approved by the stock listing committee of science and Innovation Board of Shanghai Stock Exchange on May 11, 2020, and approved by the reply on Approving the registration of initial public offering of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. (zjxk [2020] No. 1217) of China Securities Regulatory Commission on June 23, 2020, 61621142 ordinary shares (A shares) in RMB were issued in the initial public offering, with an issue price of 28.18 yuan per share and a total raised capital of 173648378156 yuan. The sponsor (lead underwriter) of this offering, Huatai United Securities Co., Ltd., will deduct the underwriting fee (including value-added tax) of 7822859436 yuan belonging to Huatai United Securities Co., Ltd. and remit the total capital of 165825518720 yuan to the following account opened by the company: Industrial And Commercial Bank Of China Limited(601398) Shanghai Zhangjiang sub branch, with an account number of 1001194909061273331. After the above amount is paid to the joint lead underwriter Citic Securities Company Limited(600030) underwriting fee and other issuance expenses (including value-added tax), the remaining funds are the net funds raised by the company, totaling 163442818764 yuan. The above raised funds have been verified by Ernst & Young Huaming Certified Public Accountants (special general partnership), and the capital verification report (Ernst & Young Huaming (2020) Yan Zi No. 60468439b01) was issued on July 17, 2020.
(II) use amount and balance of raised amount during the reporting period
As of December 31, 2021, the use and balance of the raised funds of the company are as follows:
Project amount (RMB)
The total amount of raised funds is 173648378156
Less: lead underwriter’s underwriting fee 7822859436
The total amount of raised funds actually received is 165825518720
Less: 1228888544 of the amount paid in advance by replacing the issue expenses with the raised funds
Less: the amount of issuance expenses paid in 2020 is 1153811412
Net proceeds 163442818764
Less: 13230689212 amount of self raised funds invested in advance replaced by raised funds
Less: 36453081575 yuan invested in the project of raising funds
Including: the amount invested in the project of raising funds in 2021 is 17646865043
Plus: interest income 2615206811
The balance of raised funds is 11637454788
Less: structural deposit balance 30000000000
The balance of the special account for raised funds is 86374254788
2、 Management of raised funds
(I) management of raised funds
In order to standardize the management and use of raised funds, improve the efficiency and efficiency of fund use, and protect the interests of investors, the company, in accordance with the company law, the securities law, the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies In accordance with the provisions of relevant laws, regulations and normative documents such as the Listing Rules of science and Innovation Board of Shanghai Stock Exchange (revised in December 2020) and the measures for the management of raised funds of listed companies of Shanghai Stock Exchange (revised in 2013), and in combination with the actual situation of the company, the company has formulated the management system of raised funds of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as the management system of raised funds). According to the raised funds management system, the company adopts a special account storage system for the raised funds and establishes a special account for the raised funds in the bank. The company, together with the sponsor Huatai United Securities Co., Ltd., signed the tripartite supervision agreement on the storage of special account for raised funds with China Merchants Bank Co.Ltd(600036) Shanghai Zhangjiang sub branch and China Citic Bank Corporation Limited(601998) Shanghai branch respectively, clarifying the rights and obligations of all parties.
The company and its subsidiary Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Suzhou) Co., Ltd., together with the sponsor Huatai United Securities Co., Ltd., signed the four party supervision agreement on the storage of special account for raised funds with Industrial And Commercial Bank Of China Limited(601398) Shanghai Zhangjiang science and technology sub branch; The company and its subsidiary Shanghai Shengguo Pharmaceutical Development Co., Ltd., together with the sponsor Huatai United Securities Co., Ltd. and China Citic Bank Corporation Limited(601998) Shanghai Branch signed the four party supervision agreement on the storage of special account for raised funds, clarifying the rights and obligations of all parties.
There is no significant difference between the above regulatory agreement and the model regulatory agreement of Shanghai Stock Exchange. The company has strictly followed and performed the raised funds in order to facilitate the management and use of the raised funds and supervise their use, so as to ensure that the special funds are used for special purposes.
(II) special account storage of raised funds
As of December 31, 2021, the deposit of raised funds between the company and its subsidiaries
The situation is as follows:
Balance of funds raised by the company’s bank account number (RMB)
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Suzhou) Co., Ltd. Industrial And Commercial Bank Of China Limited(601398) Shanghai Pudong soft 100107242907 Shantui Construction Machinery Co.Ltd(000680) 62139121214 Jianyuan sub branch
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. China Merchants Bank Co.Ltd(600036) Shanghai Zhangjiang sub branch 12190793201042013729454844
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. China Merchants Bank Co.Ltd(600036) Shanghai Zhangjiang sub branch 1219079320102218170228247
Shanghai Shengguo Pharmaceutical Development Co., Ltd. China Citic Bank Corporation Limited(601998) Shanghai Dahua Jinxiu sub branch 81102010141012127131864917892
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. China Merchants Bank Co.Ltd(600036) Shanghai Zhangjiang sub branch 1219079320109231840.09
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. China Citic Bank Corporation Limited(601998) Shanghai Dahua Jinxiu sub branch 8110201014401212707470348582
Total 86374254788
3、 Actual use of raised funds in 2021
(I) use of funds for investment projects with raised funds
Disclosed according to the prospectus of the company’s initial public offering of RMB common shares (A shares)
According to the application plan of the raised funds, the funds raised by stock issuance will be fully used after deducting the issuance expenses
Raise funds for investment projects and supplement working capital related to the company’s main business.
As of December 31, 2021, see “Annex 1:
Comparison table of use of raised funds “.
(II) advance investment and replacement of investment projects with raised funds
On November 5, 2020, the company held the 18th meeting of the third board of directors for review
Discussion on the adoption of the self financing plan on using the raised funds to replace the investment projects invested with the raised funds in advance
The company uses the raised funds to replace the raised funds and invest the raised funds in advance with the self raised funds
The total amount of gold investment projects is 13230689212 yuan, which is invested with raised funds
The total amount of issuance expenses paid in advance with self raised funds is 1228888544 yuan
RMB 14459577756 is used to replace the self invested funds in advance
Raise funds. The above situation of self raised funds pre invested in projects invested with raised funds has been verified by Ernst & Young Huaming Certified Public Accountants (special general partnership) and issued the special verification report on the situation of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. pre invested projects invested with raised funds with self raised funds (Ernst & Young Huaming (2020) ZZ No. 60468439b06). The independent directors of the company have expressed explicit consent to the above matters, and the sponsor Huatai United Securities Co., Ltd. has issued explicit consent verification opinions on the above matters.
(III) temporary replenishment of working capital with idle raised funds
In 2021, the company did not temporarily supplement working capital with idle raised funds.
(IV) cash management of idle raised funds and investment in related products
On August 13, 2021, the company held the 25th meeting of the third board of directors and the 14th meeting of the third board of supervisors, deliberated and approved the proposal on using part of the temporarily idle raised funds for cash management, and agreed that the company would use the temporarily idle raised funds with an amount not exceeding RMB 80 million (including this amount) for cash management, and the service life would be effective within 12 months from the date of deliberation and approval by the board of directors, Within the above limit and term, the funds can be used circularly and rolling.
In 2021, the company used idle raised funds to purchase structured deposits, and the amount of undue redemption at the end of the year was RMB 30000000, including: the amount of undue redemption of structured deposits purchased from Industrial And Commercial Bank Of China Limited(601398) Shanghai Pudong Software Park sub branch at the end of the year was RMB 2000000000; For the structured deposits purchased in China Citic Bank Corporation Limited(601998) Shanghai Dahua Jinxiu sub branch, the undue redemption amount at the end of the year is RMB 28000000000.
(V) permanent replenishment of working capital or repayment of bank loans with over raised funds
In 2021, the company did not permanently supplement working capital or repay bank loans with over raised funds.
(VI) use of over raised funds for projects under construction and new projects
In 2021, the company did not use the over raised funds for projects under construction and new projects.
(VII) utilization of raised funds
In 2021, the company did not use the surplus funds of raised funds investment projects for other raised funds investment projects or non raised funds investment projects.
(VIII) other information about the use of raised funds
In 2021, there is no other use of raised funds that need to be explained.
4、 Change the use of funds for investment projects with raised funds
In 2021, the company did not change the investment projects of raised funds.
